Actorius Innovations at ASCO Annual Meeting 2026 Publications 17 March 2026 ASCO 2026: Continual depletion of circulating tumor cells using an automated device enriched with affinity glass bead substrates in breast and CRC patient's whole blood. Automated OncoMetastat device captures and depletes CTCs in colorectal and breast cancer, aiding detection of minimal residual disease and metastasis risk. Abstract Background Despite no radiological or pathological evidence of disease, about 25–50% of stage II–III colorectal cancer (CRC) and early-stage breast cancer (BC) patients are known to experience recurrence. The presence of circulating tumor cells (CTCs) with epithelial–mesenchymal transition (EMT) traits represents aggressive systemic disease. Through autonomous oncogenic activation, epithelial cells acquire invasive properties that enable metastasis. A high EMT score combined with immune checkpoint expression, such as PD-L1, may allow tumor cells to evade immune surveillance. Following curative-intent surgery and therapy, CTCs represent minimal cellular residual disease (MCRD) and serve as strong predictors of recurrence. In this study, we present an automated extracorporeal device designed to capture, analyze, and deplete CTCs for further clinical evaluation. Methods We retrospectively analyzed 66 patients, including stage II–III CRC patients (n = 41) and breast cancer patients (n = 25). Whole blood samples were processed to deplete CTCs using the OncoMetastat device. Among the CRC patients, 12 were female and 29 were male. The average age of BC and CRC patients was 53.6 and 58 years, respectively. The device consists of a spiral channel (127 × 85 × 5 mm; spiral span: 66 mm; width: 4 mm) 3D-printed using biocompatible resin and filled with anti-EpCAM antibody–conjugated glass beads (GB). The system includes a controller and a peristaltic pump that circulates blood in and out of the spiral channels. Vibrational energy induces motion in the glass beads to enhance cell capture. Hemolysis, protein binding, leukocyte adsorption, and CTC capture efficiency were evaluated. CTC capture efficiency was compared with the CDSCO-approved OncoDiscover CTC technology in India. Blood samples were pumped into the device and incubated with affinity-enriched glass beads for 30 minutes under constant vibration (200 Hz) to enhance CTC capture and prevent blood stagnation. CTCs were confirmed using CK18⁺, DAPI⁺, and CD45⁻ markers and analyzed using an automated fluorescence microscope. Results A total of 48 CTCs were detected in 58% (38/66) of patients. CTC positivity was slightly higher in breast cancer patients (60.0%) compared with CRC patients (56.1%). The mean CTC distribution was 0.73 overall, with CRC and BC both showing mean values of 0.73 and 0.72, respectively. The negative predictive value (NPV) was determined to be 0.86 (86%). Automated scanning demonstrated 100% efficiency in detecting CTCs. Low leukocyte adhesion was observed with anti-EpCAM–coated glass beads. White blood cell (WBC) counts varied by cancer type, with mean counts of 4.9 × 10⁶/mL for breast cancer and 3.9 × 10⁶/mL for colorectal cancer, both lower than healthy controls (6.9 × 10⁶/mL). Clinically insignificant hemolysis (<1%) and minimal protein binding (~1.5%) were observed in the spiral channel. Glass beads subjected to vibrational energy demonstrated enhanced CTC sequestration, achieving over 90% cell capture efficiency compared with vibration-free conditions. Conclusions This study demonstrates efficient CTC depletion in 66 CRC and breast cancer patients using an automated extracorporeal device. Early-stage CRC and BC patients with detectable CTCs may have a higher risk of developing distant metastasis. Therefore, following complete remission, the use of an extracorporeal device to deplete CTCs could potentially reduce the risk of metastatic progression. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Made in India: The Low-Cost Blood Test Revolutionizing Cancer Care | Dr. Pankaj Chaturvedi Expert Insights 9 August 2022 Made in India: The Low-Cost Blood Test Revolutionizing Cancer Care | Dr. Pankaj Chaturvedi Dr. Pankaj Chaturvedi (Director, ACTREC) and Dr. Jayant Khandare discuss OncoDiscover, India's first indigenous CTC blood test. By detecting cancer relapse earlier than traditional scans, this groundbreaking "Made in India" technology drastically lowers patient costs and paves the way for future medical innovations. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTC monitoring detects early HNSCC in chronic tobacco users in Bangladesh. Publications 8 June 2021 ASCO 2021: CTCs demonstrate a positive biomarker in head and neck squamous cell carcinoma (HNSCC) in tobacco consuming population of Bangladesh. A study in Bangladesh found CTCs in 64% of HNSCC patients with chronic tobacco history, suggesting CTCs as a screening tool for early cancer detection. Background Tobacco consumption accounts for 1.6 million deaths annually in the South East Asia Region (SEAR). Notably, amongst the 10-20% of the global population consuming betel quid and tobacco, about an 81% concentration is in SEAR regions, including India and Bangladesh. The prevalence of HNSCC in these regions is rising alarmingly. For example, HNCs account for 23% of the total 156,775 cancer incidences in Bangladesh. Liquid biopsy tools are unavailable and expensive for most patients in this region. However, early cancer detection using tumor biomarkers, for example, circulating tumor cells (CTCs), is highly implicated. Furthermore, such biomarkers are being validated and have the potential for screening high-risk patients, such as those with a genetic predisposition or tobacco consumption. We report the first observational study in HNSCC patients in Bangladesh correlating the presence of CTCs to chronic tobacco consumption. Methods The study involved 70 cancer patients and 10 healthy volunteers (no prior cancer history). 87% of the patients had a specified history of chronic tobacco consumption. CTCs were isolated in 1.5 ml of blood using the OncoDiscover Liquid Biopsy Test, which is clinically approved by the Drug Controller General of India, and contains an enriching anti-EPCAM antibody immunomagnetic kit. CTCs are qualified as CK18+, DAPI+, and CD45-. Subsequently, CTCs were imaged using a Zeiss Axio Observer 7 and quantified for Mean Fluorescence Intensity (MFI) for clinicopathological parameters: age/gender, HNSCC sub-population, and CTC distribution. Results This is the 1st study on the Bangladesh phenotype accounting for the presence of CTCs in HNSCC patients. In this population, 34 males (66%) and 10 females (52%) accounted for 91 CTCs. CTC distribution was 0 to 6 with a mean and median of ~ 2.02 and 2, respectively. 25 patients (17 males, 8 females) were negative for any CTCs. Interestingly, 2 patients exhibited CTC clusters indicative of aggressive metastasis, in which 1 patient had no prior tobacco usage or family cancer history. There was no correlation between CTC presence in males (66%) and females (52%). Healthy volunteer samples exhibited no false positives. The MFI values ranged between 23 and 766, with mean and median MFI values of 157 and 96, respectively, indicative of CK overexpression on CTCs of HNSCC patients. Conclusions HNSCC patients with a history of chronic tobacco consumption in Bangladesh correlated with the presence of CTCs in 64% of the cases. Prospectively, CTCs may be validated as a biomarker for screening chronic tobacco users in Bangladesh to detect early cancers and HNSCC. Clinical Trial Information BMRC/Grants/2018/99 (1-100). Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTCs and PD-L1 after radiotherapy indicate MRD and possible tumor re-invasion. Publications 25 November 2024 ISLB 2024: Transit of Circulating Tumor Cells (CTC) Post Radiotherapy at Irradiated Tumor Regions in Pan-cancer Patients Study links radiotherapy exposure with circulating tumor cells and PD-L1 expression, indicating possible minimal residual disease and metastatic risk. Introduction The presence of circulating tumor cells (CTCs) is a predictor of minimal residual disease (MRD) and treatment outcomes. Abscopal effects of targeted intraoperative radiotherapy have been observed clinically, and the tumor microenvironment may influence these outcomes. Recent reports have shown activation and transit of CTCs following simulated radiotherapy from irradiated regions in vitro. Thus, the cellular extravasation and invasion phenotype cascade of CTCs in irradiated tumor regions could be highly concerning and raises several clinical questions. For the first time, we retrospectively analyzed patients who underwent radiotherapy to observe a clinical correlation between the presence of CTCs and overexpression of the PD-L1 protein in blood circulation as an indicator of minimal residual disease and a potential radiotherapy-associated effect. Methods A cohort of 26 pan-cancer patients (female = 10, male = 16) was analyzed, including cases of colorectal cancer (n = 4), lung cancer (n = 4), endometrial cancer (n = 4), head and neck cancer (n = 4), pancreatic cancer (n = 1), ovarian cancer (n = 1), renal cell carcinoma (n = 4), breast cancer (n = 2), and bone cancer (n = 2). Blood samples were analyzed retrospectively based on clinical and treatment history. Enumeration of CTCs was performed using the immunomagnetic multi-component OncoDiscover platform approved by CDSCO India, mediated by anti-EpCAM antibodies. CTCs were identified based on the presence of CK18+, PD-L1+, DAPI+, and CD45− staining using an automated Zeiss microscope in 1.5 ml of blood samples. Results In the retrospective analysis, a total of 88% (23/26) of patients showed the presence of CTCs in 1.5 ml of blood. Among these patients, 46% (n = 12/26) had undergone radiotherapy at some point during their treatment history. Three patients had received focused radiotherapy for brain metastasis with primary cancers of head and neck (1 case) and endometrium (2 cases). Among patients who underwent radiotherapy, 88% (8/9) were observed to have at least one CTC along with PD-L1 overexpression in at least one CTC. In addition, one patient who underwent radiotherapy showed the presence of a CTC cluster. Conclusions For the first time, we demonstrate the association of CTCs following radiotherapy in irradiated tumor regions. The disseminated CTCs may enhance tumor cell reinvasion through active transit in circulation, supported by a favorable microenvironmental milieu. Further validation with larger clinical cohorts across multiple cancer types is required. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

HER2 analysis on CTCs enables real-time monitoring in metastatic breast cancer. Publications 10 April 2024 AACR 2024: Evaluation of HER-2 expression on circulating tumor cells as a real time biomarker in advanced breast cancer HER2 analysis on circulating tumor cells using the OncoDiscover® platform enables real-time, non-invasive profiling for improved metastatic breast cancer treatment decisions. Introduction: Breast cancer accounts for 12.5% of all new annual cancer cases worldwide. Cases classified as HER2-positive tend to proliferate, metastasize, and often lead to relapse. HER2 is one of the most valid tumor markers and is widely used as a diagnostic and prognostic biomarker in metastatic breast cancer (MBC). Thus, analyzing the expression of HER2 on circulating tumor cells (CTCs) can offer a real-time dynamic biomarker for guiding treatment options between endocrine therapy and chemotherapy in advanced breast cancer. Functional assays on CTCs with the HER2 biomarker offer evolving diagnostic opportunities, especially when tissue samples are not accessible or are inadequate. Methods: Retrospectively, blood samples from 179 breast cancer patients were analyzed for the presence of CTCs using the OncoDiscover® platform approved by the Drug Controller General of India (CDSCO). The platform consists of an immunomagnetic multi-component system mediated by anti-EpCAM antibodies. The isolated cells were immunostained using the nuclear dye DAPI along with CK18, CD45, and HER2 antibodies. CTCs were identified by the presence of HER2-positive, CK18-positive, DAPI-positive, and CD45-negative staining. Validation of HER2 expression on CTCs was analyzed based on the linear intensity gradients of fluorescence signals. CTCs were termed HER2-negative when weak or no detectable fluorescence signal was observed and HER2-positive when high fluorescence signals were detected. Results: Among the cohort of 179 patient samples, 63.68% of samples showed the presence of CTCs, with counts ranging from 1–7 CTCs. Among these, 47.84% of the detected CTCs showed HER2 expression. The mean fluorescence intensity value for HER2 expression in CTCs was found to be 3.23. The observed fluorescence intensity further emphasizes the robustness of CTCs as a viable source for molecular characterization. Conclusion: Integration of HER2 analysis on CTCs into the clinical assessment of metastatic breast cancer may offer a non-invasive, real-time strategy for tumor profiling and may help pave the way for more precise and tailored therapeutic interventions. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations | Dainik Jagran Press Release 14 March 2026 Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer. Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer. Click the button below to read the full story Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTCs and PD-L1 in sarcoma indicate minimal residual disease and need for monitoring. Publications 9 May 2025 Accounts of circulating tumor cells and CTC clusters with PD-L1 expression in sarcoma patients Study shows circulating tumor cells with PD-L1 expression and clusters in sarcoma, indicating minimal residual disease and need for long-term monitoring. Abstract Background: Sarcomas are characterized by significant heterogeneity, diverse histological subtypes, and variable clinical behavior. Dynamic epithelial-to-mesenchymal transition (EMT) processes in solid tumors contribute to disease aggressiveness. Characterization of circulating tumor cells (CTCs) in sarcomas remains challenging due to the lack of well-defined, cell-specific markers and limited molecular characterization. Compared with adenocarcinomas, studies on sarcoma-derived CTCs are relatively limited. Therefore, isolation and characterization of CTCs, including assessment of protein expression and cellular transitions using affinity ligands such as anti-epithelial cell adhesion molecule (EpCAM) antibodies, may improve clinical outcomes in sarcoma patients. The role of CTCs as minimal cellular residual disease (MCRD) is particularly relevant post-treatment, including after curative-intent surgery. Objective: To evaluate the prevalence of CTCs and CTC clusters as indicators of minimal cellular residual disease (MCRD), along with PD-L1 expression, in sarcoma patients. Methods: In this retrospective study, peripheral blood samples from 97 sarcoma patients (55.95% male and 44.05% female) were analyzed for the presence of CTCs, PD-L1 expression, and CTC clusters. CTCs were isolated using the OncoDiscover platform approved by CDSCO from 1.5 mL of blood. The platform utilizes a multifunctional magneto-nanosystem mediated by anti-EpCAM antibodies. CTCs were identified as EpCAM⁺, CK18⁺, DAPI⁺, and CD45⁻ cells. PD-L1 expression on CTCs was quantified based on linear fluorescence intensity gradients using image acquisition on an automated Zeiss microscope. Results: Among the 97 patients, 86.59% had baseline CTC assessments, while 13.40% had follow-up samples. At baseline analysis, 68.04% (n = 66) of patients demonstrated ≥1 CTC per 1.5 mL of blood. The CTC count ranged from 1 to 6 cells, with a mean value of 1.17. Additionally, 61.44% (n = 51) of patients with detectable CTCs exhibited PD-L1 expression, with a mean value of 0.92. The highest proportion of CTCs (31.11%, n = 28) and CTC clusters (6.14%, n = 7) was observed in the 31–40-year age group. Conclusions: The presence of CTCs with CTC clusters and PD-L1 expression suggests minimal cellular residual disease (MCRD) and may indicate aggressive disease behavior in sarcoma patients. Following treatment, the detection of such CTCs may be associated with metastasis progression. Therefore, longitudinal monitoring of these patients is recommended to support improved clinical outcomes. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells Publications 27 January 2026 Manuscript: Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells Circulating tumor cells (CTCs), cancer cells shed from primary tumors into the bloodstream, are emerging as dynamic, non-invasive biomarkers for real-time cancer monitoring, especially when tissue biopsies are inaccessible or inadequate... Simple summary Circulating tumor cells (CTCs), which are cancer cells shed from primary tumors into the bloodstream, are emerging as dynamic, non-invasive biomarkers for real-time cancer monitoring, especially when tissue biopsies are inaccessible or inadequate. Unlike static tissue samples, CTCs allow repeated assessments that track tumor evolution, therapeutic response, and minimal residual disease. Hence, CTCs offer a minimally invasive, real-time alternative to tissue biopsies for cancer monitoring, particularly through surface protein biomarkers like PD-L1, HER2, and EGFR. As detection technologies improve and the clinical relevance of CTCs continues to be established, CTC profiling is poised to significantly influence the future of precision oncology. Abstract Circulating tumor cells (CTCs) are shed from the primary tumor into the bloodstream and represent dynamic molecular biomarkers for monitoring the progression of cancer. While profiling tumor tissues with overexpression of cell surface markers, such as PD-L1 or HER2, is standard in guiding therapy, tissue samples are often inaccessible and inadequate, especially post-surgery or in cases of recurrence. Emerging clinical evidence indicates that CTC counts and biomarker surface expression can predict prognosis and therapeutic resistance more accurately than imaging or tissue-based approaches. Recent advancements in CTC detection methods, based on physical properties or surface markers (e.g., EpCAM), coupled with next-generation sequencing (NGS), have enabled the isolation of these rare cells and their molecular characterization. Consequently, CTCs provide a real-time alternative, enabling repeated, longitudinal assessment of tumor phenotype and therapeutic response. This review emphasizes the translational potential of surface protein biomarkers on CTCs for profiling, namely PD-L1, HER2, and EGFR, as a clinically actionable approach to stratify patients, guide immunotherapy decisions, and monitor minimal residual disease (MRD), especially when longitudinal tissue biopsies are not feasible. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Combined ctDNA and CTC analysis improves MRD detection and cancer progression monitoring. Publications 3 June 2024 ASCO 2024: Association of complementing ctDNA and CTCs load on stable and progressive disease in treated patients. Complementary ctDNA and CTC biomarkers reveal minimal residual disease and predict cancer progression after curative-intent treatment. Background: Post curative-intent surgery and therapy, the presence of circulating tumor DNA (ctDNA) load represents minimal residual disease (MRD). Conversely, the presence of circulating tumor cells (CTCs) in stage I–II cancer or even in disease-free survival (DFS) patients indicates occult cellular residual disease (CRD) with undetectable micrometastasis. These complementary biomarkers in patients undergoing treatment act as indicators of non-responsiveness, suggesting the need for treatment modifications. Methods: Retrospectively, we monitored a cohort of 46 cancer patients for MRD using ctDNA and CTCs who were treated or undergoing treatment (e.g., lung, breast, colon, and head and neck cancer; n = 14, 7, 6, and 4, respectively). The OncoMonitor test detected single nucleotide variations (SNVs), small insertions and deletions (INDELs), copy number variations (CNVs), and translocations (fusions). Libraries were prepared using a hybridization-capture method covering 1000 targets with a mean sequencing depth of 5000× on the Illumina NextSeq 2000 in paired-end mode (150 × 2). Variant calling was performed using a proprietary bioinformatics pipeline, iCare. CTCs were isolated using the OncoDiscover platform, which possesses an anti-EpCAM antibody-based immunomagnetic system per 1.5 mL of blood. CTCs were confirmed using CK18+, PD-L1, and CD45 markers with a motorized fluorescence microscope. Results: From ctDNA analysis, 47.82% (n = 22) of patients were identified with at least one actionable genomic finding. Among these, 13.04% (n = 6) of patients showed EGFR driver mutations. Additionally, 19.56% (n = 9) of patients were identified with either EGFR driver, KRAS, or PI3K passenger mutations, while 4.34% (n = 2) were identified with ALK–EML4 fusion. The average ctDNA load obtained in patients with progressive disease (n = 26) was 8.2 molecules per 1 mL of plasma. At least one CTC was detected in 61.53% (n = 16) of progressive disease patients, with the highest count of four CTCs identified in 7.69% (n = 2) of patients. Only 30% (n = 6) of patients with stable disease were identified with at least one genomic finding from a total of 20 patients upon ctDNA analysis, with an average ctDNA load of 2.2 molecules per 1 mL of plasma. Patients with clinically progressive disease showed ctDNA load approximately fourfold higher than those with stable disease during treatment. No patients with stable disease were identified with four CTCs, as opposed to 7.69% in the progressive disease cohort during treatment. Conclusions: We observed that ctDNA and CTCs complement MRD status even after curative-intent surgery and therapy, with the potential to identify patients likely to experience disease progression. Our findings strongly indicate a positive correlation between ctDNA load, the number of detected CTCs, and disease progression based on radiological findings. These biomarkers can support practical clinical decision-making. Further studies are necessary to validate these findings and improve follow-up strategies for better clinical outcomes. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

OncoDiscover enables early cancer spread detection and faster diagnosis. | BS Article Press Release 24 August 2019 Pune scientists discover tech, first in India, to detect early spread of cancer. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process… A team of Pune scientists have discovered a technology that can detect within mere hours, the spread of cancer and claim that the new finding reduces considerably the time taken for detecting the disease. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process. Presently, in India, the final diagnosis report to detect the spread of cancer takes about 12 days whereas, with OncoDiscover technology, doctors can detect it in a mere 3.5 hours. Dr Khandare told ANI, "We felt the need for this technology because global cancer is spreading. 90 per cent of the people get to know they have cancer when it is at the second stage but through this technology, we can try saving that 90 per cent. This technology is needed to detect cancer at an early stage." View full article Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Liquid biopsy may replace invasive procedure to detect cancer Press Release 23 April 2020 Times of India | Liquid biopsy may replace invasive procedure to detect cancer: Experts Liquid biopsy may replace invasive procedure to detect cancer: Experts Read the article Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Discover Actorius' journey. Learn how our innovation-driven, impact-obsessed start-up is revolutionizing early cancer detection. Our story so far An innovation-driven organisation 11000+ Patients Served 450+ Doctors Trust Us 100+ Publications 13+ Years of Excellence Innovation Driven Impact-obsessed Who we are About Actorius We innovate and create bio materials that have critical applications in the field of life sciences, drug delivery and medical diagnostics. We work with a vision to advance and improve human health. Trusted by: Mission, Vision & Purpose Innovating with Intent Our mission, vision, and purpose reflect our commitment to meaningful progress and measurable outcomes. Mission To develop innovative methodologies to develop diagnostic tests that provide early indicators of oncogenesis and enable informed treatment strategies. Vision To collectively advance and improve human health by developing biomedical innovations into practical applications that have wider reach, accessibility and affordability. Purpose To positively impact everyone, by developing solutions that have reduced time to decision making and providing precise information for a chosen course of action. Our Values What We Stand For Our values define our commitment to rigorous science, responsibility, and meaningful impact. Work on challenges with cutting-edge science and innovation. Work towards making it accessible and affordable to the masses. Ensure critical clinical validations for every outcome. Bio-materials with high specificity, efficiency and sensitivity. Scientific disciplines with interdisciplinary intelligence at the core. Take every little step to ensure cancer patient’s lives are saved. Focused on creating novel cancer diagnostic tests. Know more Rigour in every action. Every product undergoes intense design and development. Leaving no stone unturned. We follow the most stringent quality norms like ISO13485 and regulatory requirements. Passionate and emphatic. We are committed to developing solutions for unmet medical needs. We build high-risk innovative products, which have a very long life-cycle, using novel biomaterials. Detect cancer relapse early, when it can be cured. We are committed to bringing stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care. India has a breakthrough in early cancer detection. Know More